Christian Récher

4 days ago | nature.com | Delphine Lebon |Nicolas Duployez |Christophe Willekens |Thomas Cluzeau |Christian Récher |Mathilde Hunault-Berger | +1 more

AbstractFront-line treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in patients with low-/intermediate-risk acute promyelocytic leukemia (APL). However, for high-risk (HR) patients (defined as those with a white blood cell count ≥ 10×10⁹/L), the role of ATRA-ATO is subject to debate, and study data are scarce.

Feb 12, 2024 | onlinelibrary.wiley.com | Keith W Pratz |Brian A. Jonas |Vinod Pullarkat |Michael J. Thirman |Jacqueline Garcia |Hartmut Döhner | +9 more

1 INTRODUCTION Acute myeloid leukemia (AML) is a heterogenous neoplasm characterized by proliferation of immature myeloid cells in bone marrow and peripheral blood, leading to failure of normal hematopoiesis.1 AML is the most common acute leukemia in adults, with a median age at diagnosis of 68 years.